rac-Erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
CAS: 58337-38-5
Ref. 3D-FE16560
1mg | Discontinued | ||
2mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued |
Product Information
- EHNA hydrochlorideerythro-9-Amino-b-hexyl--a-methyl-9H-purine-9-ethanol hydrochlorideerythro-9-(2-Hydroxy-3-nonyl)-adenine hydroch loride
- (R*,S*)-(+-)-6-Amino-beta-hexyl-alpha-methyl-9H-purine-9-ethanol
- 9H-purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-
- 9H-Purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, (R*,S*)-(+-)-
- 3-(6-Amino-9H-purin-9-yl)nonan-2-ol
Erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride (EHA) is a molecule that has been shown to inhibit skin tumor formation in mice. It has also been shown to be effective against solid tumours and cancer stem cells in mice. EHA is an amino acid derivative that inhibits the growth of cancer cells by targeting the molecules involved in the formation of skin tumors. The mechanism of action involves the inhibition of protein synthesis and DNA replication, as well as the induction of apoptosis. EHA can be used for pharmaceutical preparations against skin cancer and other solid tumours.